Arena Pharmaceuticals Inc.

Address: 66 Hudson Boulevard East

Sponsor Overview

assignment

Specializations

Crohn’s disease

Arena Pharmaceuticals Inc. is active in clinical research for Crohn’s disease, with a focus on moderately to severely active inflammatory bowel disease and oral therapeutic options. The company’s trials examine treatment effects in adults with ongoing intestinal inflammation and related disease burden.

Induction therapy
Maintenance treatment
Oral immunomodulatory therapy

Its research activity includes multicenter work across international sites in patients with active gastrointestinal disease.

Ulcerative colitis

The sponsor also concentrates on ulcerative colitis, including moderately to severely active ulcerative colitis and long-term disease management. Clinical studies address treatment response in adolescents and adults with persistent colonic inflammation.

Clinical remission
Long-term safety
Maintenance therapy

Research in this area spans ongoing treatment evaluation in both newly treated and continuing patient populations.

Adolescent gastrointestinal disease

Arena Pharmaceuticals Inc. includes adolescent ulcerative colitis in its clinical portfolio, reflecting interest in younger patients with chronic inflammatory bowel disease. The work examines therapeutic outcomes in a pediatric-adolescent population requiring sustained disease control.

Adolescent treatment response
Pediatric inflammatory bowel disease
Age-specific efficacy

This area links gastrointestinal immunology with age-appropriate management of chronic relapsing disease.

Trial Name	Country	Status
C5041010 (APD334-207) An Open Label, Single Arm Study to Evaluate the Efficacy, Pharmacokinetics, and Safety of Etrasimod in Adolescent Participants with Moderately to Severely Active Ulcerative Colitis	Austria Belgium Poland Slovakia Spain	Recruiting
Efficacy and Safety Evaluation of Oral Etrasimod Arginine as Induction and Maintenance Therapy in Moderately to Severely Active Crohn's Disease	Austria Belgium Bulgaria Croatia Czechia Denmark France Germany Greece Hungary Italy Poland Slovakia Spain The Netherlands	Not Recruiting
Open-Label Extension Study Assessing Long-Term Safety of Etrasimod Arginine in Patients with Moderately to Severely Active Ulcerative Colitis	Belgium Bulgaria Czechia Estonia France Germany Hungary Italy Lithuania Poland Portugal Romania Slovakia Spain	Not Recruiting